MiMedx October 16 Meeting With FDA Postponed Due To Government Shutdown

MiMedx Group

announced today that the Company's meeting with the Food and Drug Administration ("FDA") that was scheduled for today, October 16, 2013, to discuss the recent Untitled Letter has been postponed. The meeting was postponed as a result of the partial Federal government shutdown. The FDA has not yet advised the Company when the rescheduled meeting will be held.  Parker H. Petit, Chairman and CEO, said, "As part of the partial Federal government shutdown, some of the key participants in the meeting remain on furlough, and the meeting could not be held today. We are anxious to have the opportunity to meet with the FDA to discuss our position that our micronized products are minimally manipulated and should continue to be marketed solely under Section 361 of the Public Health Service Act and the FDA's regulation under 21 CFR 1271. We look forward to working with the FDA to resolve this issue as quickly as possible." When the Company is advised of the rescheduled meeting date, MiMedx will communicate it to its shareholders. As the